Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Apatinib combined with DOS neoadjuvant therapy for locally advanced gastric cancer
ChiCTR1800019223Phase 4Not yet recruiting
- Sponsor
- First Affiliated Hospital of Chongqing Medical University
- Start
- Nov 2018
- Modality
- Classical Binding Small Molecules → Small Molecules, Covalent Small Molecules → Small Molecules, Nucleic Acid-Directed Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of Rivoceranib, docetaxel, oxaliplatin and tegafur in gastric cancer (GC), sponsored by First Affiliated Hospital of Chongqing Medical University. Primary endpoints: Surgical resection rate and Surgical cure rate. Planned start Nov 2018; status: not yet recruiting.
02
Drugs
Rivoceranibdocetaxeloxaliplatintegafur
03
Conditions
gastric cancer (GC)
Beyond the preview
Go deeper on ChiCTR1800019223.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR1800019223.